Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tachycardia, Ventricular | 13 | 2024 | 131 | 4.610 |
Why?
|
| Genetic Therapy | 28 | 2024 | 852 | 4.010 |
Why?
|
| Atrial Fibrillation | 19 | 2024 | 884 | 3.340 |
Why?
|
| Arrhythmias, Cardiac | 14 | 2024 | 162 | 2.670 |
Why?
|
| Gene Transfer Techniques | 19 | 2024 | 325 | 2.540 |
Why?
|
| Myocardial Infarction | 9 | 2024 | 921 | 2.480 |
Why?
|
| Long QT Syndrome | 6 | 2023 | 31 | 1.750 |
Why?
|
| Genetic Vectors | 14 | 2024 | 929 | 1.460 |
Why?
|
| Swine | 16 | 2023 | 397 | 1.290 |
Why?
|
| Heart Failure | 7 | 2022 | 965 | 1.270 |
Why?
|
| Heart Atria | 9 | 2024 | 137 | 1.210 |
Why?
|
| Cicatrix | 5 | 2024 | 62 | 1.200 |
Why?
|
| Connexin 43 | 3 | 2015 | 14 | 1.180 |
Why?
|
| Myocardium | 12 | 2023 | 302 | 1.110 |
Why?
|
| Heart Arrest | 4 | 2024 | 177 | 1.000 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2023 | 272 | 0.990 |
Why?
|
| Electrocardiography | 11 | 2024 | 555 | 0.930 |
Why?
|
| Catheter Ablation | 6 | 2022 | 160 | 0.920 |
Why?
|
| Animals | 40 | 2024 | 21467 | 0.870 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 137 | 0.860 |
Why?
|
| Metaplasia | 1 | 2024 | 19 | 0.840 |
Why?
|
| Heart Conduction System | 8 | 2014 | 50 | 0.810 |
Why?
|
| Adenoviridae | 11 | 2010 | 132 | 0.760 |
Why?
|
| Atrial Remodeling | 2 | 2020 | 23 | 0.730 |
Why?
|
| Disease Models, Animal | 8 | 2022 | 2327 | 0.720 |
Why?
|
| Heart | 5 | 2004 | 298 | 0.710 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2019 | 35 | 0.660 |
Why?
|
| Defibrillators, Implantable | 6 | 2010 | 273 | 0.660 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 3 | 2010 | 7 | 0.650 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2010 | 367 | 0.630 |
Why?
|
| Heart Rate | 7 | 2023 | 334 | 0.630 |
Why?
|
| Myocytes, Cardiac | 3 | 2017 | 123 | 0.620 |
Why?
|
| Humans | 45 | 2024 | 65654 | 0.600 |
Why?
|
| Heart Diseases | 1 | 2022 | 223 | 0.590 |
Why?
|
| ERG1 Potassium Channel | 5 | 2023 | 6 | 0.540 |
Why?
|
| Parvovirinae | 1 | 2017 | 3 | 0.530 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2017 | 14 | 0.530 |
Why?
|
| Epigenomics | 1 | 2018 | 62 | 0.520 |
Why?
|
| Viral Tropism | 1 | 2017 | 55 | 0.510 |
Why?
|
| Potassium Channels, Voltage-Gated | 3 | 2022 | 32 | 0.470 |
Why?
|
| Gene Editing | 1 | 2020 | 331 | 0.470 |
Why?
|
| Biological Therapy | 1 | 2016 | 16 | 0.470 |
Why?
|
| Transduction, Genetic | 1 | 2017 | 242 | 0.470 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 531 | 0.460 |
Why?
|
| Coronary Artery Disease | 2 | 2018 | 326 | 0.450 |
Why?
|
| Calcium | 3 | 2016 | 587 | 0.440 |
Why?
|
| Up-Regulation | 2 | 2016 | 376 | 0.440 |
Why?
|
| Cardiovascular Diseases | 3 | 2018 | 872 | 0.440 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 3 | 2004 | 15 | 0.430 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 5 | 2022 | 24 | 0.410 |
Why?
|
| Stress, Physiological | 1 | 2015 | 210 | 0.390 |
Why?
|
| Peptides | 1 | 2017 | 593 | 0.390 |
Why?
|
| Cardiac Pacing, Artificial | 7 | 2011 | 35 | 0.390 |
Why?
|
| Atrial Function, Left | 3 | 2020 | 32 | 0.380 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2004 | 344 | 0.370 |
Why?
|
| Connexins | 1 | 2011 | 9 | 0.360 |
Why?
|
| Perfusion | 3 | 2003 | 76 | 0.350 |
Why?
|
| Rabbits | 6 | 2023 | 342 | 0.340 |
Why?
|
| Heart Ventricles | 3 | 2022 | 267 | 0.330 |
Why?
|
| Action Potentials | 6 | 2015 | 113 | 0.320 |
Why?
|
| Myocardial Contraction | 3 | 2006 | 88 | 0.300 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 152 | 0.290 |
Why?
|
| Time Factors | 8 | 2016 | 3777 | 0.290 |
Why?
|
| Models, Animal | 2 | 2010 | 242 | 0.270 |
Why?
|
| Risk Factors | 6 | 2023 | 5466 | 0.250 |
Why?
|
| Gene Targeting | 1 | 2007 | 77 | 0.250 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 23 | 0.240 |
Why?
|
| Atrioventricular Node | 3 | 2004 | 9 | 0.230 |
Why?
|
| Treatment Outcome | 9 | 2016 | 5820 | 0.230 |
Why?
|
| Cyclic GMP | 2 | 2007 | 33 | 0.230 |
Why?
|
| Staphylococcal Infections | 1 | 2006 | 131 | 0.210 |
Why?
|
| Cell Communication | 1 | 2005 | 135 | 0.210 |
Why?
|
| Lipomatosis | 1 | 2024 | 7 | 0.210 |
Why?
|
| Sus scrofa | 4 | 2017 | 30 | 0.210 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2004 | 49 | 0.200 |
Why?
|
| Guinea Pigs | 2 | 2022 | 86 | 0.190 |
Why?
|
| Tissue Distribution | 1 | 2023 | 292 | 0.190 |
Why?
|
| Risk Assessment | 3 | 2023 | 2113 | 0.180 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2022 | 15 | 0.180 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2017 | 503 | 0.170 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2016 | 102 | 0.170 |
Why?
|
| Echocardiography | 3 | 2020 | 513 | 0.170 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2001 | 4 | 0.170 |
Why?
|
| Adenoviruses, Human | 1 | 2001 | 10 | 0.170 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2001 | 27 | 0.170 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 22 | 0.170 |
Why?
|
| MicroRNAs | 2 | 2020 | 714 | 0.170 |
Why?
|
| Lymphokines | 1 | 2001 | 67 | 0.170 |
Why?
|
| Electrophysiology | 3 | 2008 | 89 | 0.170 |
Why?
|
| Transfection | 3 | 2015 | 700 | 0.160 |
Why?
|
| Male | 12 | 2022 | 31297 | 0.150 |
Why?
|
| Mutation | 4 | 2015 | 2672 | 0.150 |
Why?
|
| Telemetry | 1 | 2019 | 17 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2016 | 58 | 0.140 |
Why?
|
| DNA, Recombinant | 1 | 2018 | 47 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 530 | 0.140 |
Why?
|
| Female | 11 | 2022 | 34310 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 117 | 0.130 |
Why?
|
| Serotonin | 1 | 1998 | 62 | 0.130 |
Why?
|
| Advisory Committees | 1 | 2018 | 111 | 0.130 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 6 | 0.130 |
Why?
|
| Virus Attachment | 1 | 2017 | 18 | 0.130 |
Why?
|
| Bradycardia | 2 | 2010 | 33 | 0.130 |
Why?
|
| Syncope | 2 | 2010 | 42 | 0.130 |
Why?
|
| Virulence | 1 | 2017 | 199 | 0.130 |
Why?
|
| Genes, Viral | 1 | 1997 | 57 | 0.130 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2193 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2017 | 130 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2019 | 3164 | 0.130 |
Why?
|
| Middle Aged | 7 | 2024 | 18440 | 0.120 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 157 | 0.120 |
Why?
|
| Electric Countershock | 2 | 2010 | 109 | 0.120 |
Why?
|
| Capsid Proteins | 1 | 2017 | 107 | 0.120 |
Why?
|
| Genes, Reporter | 3 | 2005 | 257 | 0.120 |
Why?
|
| Voltage-Sensitive Dye Imaging | 1 | 2015 | 1 | 0.120 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 35 | 0.120 |
Why?
|
| Random Allocation | 2 | 2014 | 200 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2023 | 1335 | 0.120 |
Why?
|
| Serine | 1 | 2015 | 90 | 0.110 |
Why?
|
| Dependovirus | 2 | 2017 | 760 | 0.110 |
Why?
|
| Animals, Newborn | 1 | 2015 | 241 | 0.110 |
Why?
|
| GTP-Binding Protein alpha Subunit, Gi2 | 3 | 2004 | 5 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 408 | 0.110 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2014 | 40 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 626 | 0.100 |
Why?
|
| Aged | 8 | 2020 | 15090 | 0.100 |
Why?
|
| Cell Line | 1 | 2017 | 2030 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2015 | 963 | 0.090 |
Why?
|
| beta-Galactosidase | 2 | 2005 | 84 | 0.090 |
Why?
|
| Stilbenes | 1 | 2013 | 22 | 0.090 |
Why?
|
| Choroidal Neovascularization | 1 | 2013 | 28 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 83 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 169 | 0.090 |
Why?
|
| Sinoatrial Node | 1 | 2011 | 3 | 0.090 |
Why?
|
| Sick Sinus Syndrome | 1 | 2011 | 5 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 735 | 0.080 |
Why?
|
| Macular Degeneration | 1 | 2013 | 196 | 0.080 |
Why?
|
| Oxygen | 1 | 2011 | 321 | 0.070 |
Why?
|
| Tachycardia | 1 | 2008 | 28 | 0.070 |
Why?
|
| Phenotype | 2 | 2010 | 1235 | 0.070 |
Why?
|
| Genotype | 1 | 2010 | 674 | 0.070 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 240 | 0.070 |
Why?
|
| Channelopathies | 1 | 2007 | 5 | 0.070 |
Why?
|
| Wound Healing | 1 | 2008 | 193 | 0.070 |
Why?
|
| Endocardium | 1 | 2006 | 14 | 0.060 |
Why?
|
| Thrombomodulin | 1 | 2006 | 17 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2007 | 2262 | 0.060 |
Why?
|
| Biomarkers | 3 | 2020 | 1487 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2020 | 2639 | 0.060 |
Why?
|
| Adenosine | 1 | 2007 | 79 | 0.060 |
Why?
|
| Stroke Volume | 2 | 2005 | 345 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2007 | 125 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2007 | 164 | 0.060 |
Why?
|
| Equipment Safety | 1 | 2005 | 29 | 0.060 |
Why?
|
| Tensile Strength | 1 | 2005 | 32 | 0.050 |
Why?
|
| Trypsin | 1 | 2005 | 43 | 0.050 |
Why?
|
| Poloxamer | 1 | 2005 | 16 | 0.050 |
Why?
|
| Diltiazem | 1 | 2004 | 2 | 0.050 |
Why?
|
| Propanolamines | 1 | 2004 | 10 | 0.050 |
Why?
|
| Pericardium | 1 | 2005 | 35 | 0.050 |
Why?
|
| Digoxin | 1 | 2004 | 23 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 183 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 113 | 0.050 |
Why?
|
| Femoral Vein | 1 | 2004 | 20 | 0.050 |
Why?
|
| Calcium Channels, L-Type | 1 | 2004 | 26 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 58 | 0.050 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 46 | 0.050 |
Why?
|
| Recurrence | 2 | 2016 | 664 | 0.050 |
Why?
|
| Potassium Channel Blockers | 1 | 2004 | 23 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2006 | 535 | 0.050 |
Why?
|
| Survival Rate | 1 | 2006 | 847 | 0.050 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2004 | 42 | 0.050 |
Why?
|
| Apoptosis | 2 | 2011 | 1100 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 1634 | 0.050 |
Why?
|
| Fibrosis | 1 | 2004 | 172 | 0.050 |
Why?
|
| Sex Factors | 1 | 2006 | 995 | 0.050 |
Why?
|
| Problem-Based Learning | 1 | 2003 | 38 | 0.050 |
Why?
|
| Aging | 1 | 2009 | 775 | 0.050 |
Why?
|
| Solutions | 1 | 2003 | 63 | 0.050 |
Why?
|
| Acute Disease | 1 | 2004 | 663 | 0.050 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2002 | 34 | 0.050 |
Why?
|
| Rats | 2 | 2006 | 2002 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2004 | 491 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 54 | 0.050 |
Why?
|
| Blood Vessels | 1 | 2002 | 63 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2003 | 137 | 0.040 |
Why?
|
| Purinones | 1 | 2001 | 1 | 0.040 |
Why?
|
| Nitric Oxide Donors | 1 | 2001 | 6 | 0.040 |
Why?
|
| omega-N-Methylarginine | 1 | 2001 | 8 | 0.040 |
Why?
|
| Nitroglycerin | 1 | 2001 | 11 | 0.040 |
Why?
|
| Guanylate Cyclase | 1 | 2001 | 11 | 0.040 |
Why?
|
| Sildenafil Citrate | 1 | 2001 | 14 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 22 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2001 | 45 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2003 | 180 | 0.040 |
Why?
|
| Sulfones | 1 | 2001 | 43 | 0.040 |
Why?
|
| Isoquinolines | 1 | 2001 | 30 | 0.040 |
Why?
|
| Purines | 1 | 2001 | 43 | 0.040 |
Why?
|
| Transformation, Genetic | 1 | 2000 | 31 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 2000 | 52 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2001 | 142 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 5657 | 0.040 |
Why?
|
| Piperazines | 1 | 2001 | 86 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 2496 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2020 | 129 | 0.040 |
Why?
|
| Pyridines | 1 | 2001 | 120 | 0.040 |
Why?
|
| Adult | 4 | 2015 | 17511 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 234 | 0.040 |
Why?
|
| Containment of Biohazards | 1 | 2018 | 6 | 0.040 |
Why?
|
| Cell Culture Techniques | 2 | 2014 | 195 | 0.030 |
Why?
|
| Bradykinin | 1 | 1998 | 8 | 0.030 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1998 | 30 | 0.030 |
Why?
|
| Permeability | 1 | 1998 | 52 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2016 | 3329 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 1998 | 55 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 159 | 0.030 |
Why?
|
| Lac Operon | 1 | 1997 | 26 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1998 | 491 | 0.030 |
Why?
|
| Luciferases | 1 | 1997 | 107 | 0.030 |
Why?
|
| Dogs | 2 | 2011 | 326 | 0.030 |
Why?
|
| Mice | 2 | 2011 | 11174 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1288 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 149 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 294 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2015 | 67 | 0.030 |
Why?
|
| Cryosurgery | 1 | 2015 | 28 | 0.030 |
Why?
|
| Adolescent | 1 | 2006 | 6350 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2014 | 20 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2014 | 23 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2014 | 36 | 0.030 |
Why?
|
| Alginates | 1 | 2014 | 50 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 328 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2014 | 133 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2006 | 6948 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1116 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 606 | 0.020 |
Why?
|
| Fever | 1 | 2013 | 65 | 0.020 |
Why?
|
| Headache | 1 | 2013 | 58 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 934 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 193 | 0.020 |
Why?
|
| Angiotensin II | 1 | 2011 | 25 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1144 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2011 | 69 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 1791 | 0.020 |
Why?
|
| United States | 2 | 2018 | 8166 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 237 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 1026 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2007 | 22 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1291 | 0.020 |
Why?
|
| Electrodes | 1 | 2007 | 39 | 0.020 |
Why?
|
| Hypertension | 1 | 2013 | 616 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2006 | 184 | 0.020 |
Why?
|
| Ion Channel Gating | 1 | 2004 | 44 | 0.010 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 2004 | 2 | 0.010 |
Why?
|
| Injections | 1 | 2004 | 84 | 0.010 |
Why?
|
| Phenethylamines | 1 | 2004 | 10 | 0.010 |
Why?
|
| Chromans | 1 | 2004 | 16 | 0.010 |
Why?
|
| Ventricular Function | 1 | 2004 | 22 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 2004 | 53 | 0.010 |
Why?
|
| Heart Block | 1 | 2004 | 21 | 0.010 |
Why?
|
| Health Education | 1 | 2005 | 190 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 252 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2004 | 169 | 0.010 |
Why?
|
| Health Policy | 1 | 2005 | 191 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2004 | 190 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 405 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2004 | 168 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2005 | 400 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2004 | 134 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 2002 | 14 | 0.010 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2002 | 15 | 0.010 |
Why?
|
| Isoproterenol | 1 | 2002 | 37 | 0.010 |
Why?
|
| Cell Size | 1 | 2002 | 41 | 0.010 |
Why?
|
| Transgenes | 1 | 2002 | 207 | 0.010 |
Why?
|